DOCSLIB.ORG

List of Publications, Influenza Vaccine and Vaccine Policy, 2010–2011

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
List of Publications, Influenza Vaccine and Vaccine Policy, 2010–2011 APPENDIX 9 List of publications, influenza vaccine and vaccine policy, 2010–2011 1. 2010. A call for mandatory flu vaccinations. OR.Manager. 26:5. 2. 2010. ACOG Committee Opinion No. 468: Influenza vaccination during pregnancy. Obstet.Gynecol. 116:1006–1007. doi:10.1097/AOG.0b013e3181fae845 [doi];00006250-201010000-00040 [pii]. 3. 2010. Antigenic and genetic characteristics of influenza A(H5N1)and influenza A(H9N2) viruses and candidate vaccine viruses developed for potential use in human vaccines. Wkly.Epidemiol.Rec. 85:418–424. 4. 2010. European Medicines Agency updates on the review of Pandemrix and reports of narcolepsy. Euro.Surveill 15. 5. 2010. Flu vaccination challenge enters third season with room for more participants and better rates. Jt.Comm Perspect. 30:9, 11. 6. 2010. Future pandemic vaccines may face suspicion. Hum.Vaccin. 6:526. doi:12826 [pii]. 7. 2010. Global Advisory Committee on Vaccine Safety,3–4 December 2009. Wkly.Epidemiol.Rec. 85:29–33. 8. 2010. H1N1 and this flu season. The pandemic may be over, but the virus is still around, and children, young adults, and pregnant women are susceptible. Harv.Health Lett. 36:1–2. 9. 2010. H1N1 vaccine in children – one dose seems to provide some protection . Child Health Alert. 28:1. 10. 2010. Interim results: influenza A (H1N1) 2009 monovalent and seasonal influenza vaccination coverage among health-care personnel – United States, August 2009–January 2010. MMWR Morb. Mortal.Wkly.Rep. 59:357–362. doi:mm5912a1 [pii]. 11. 2010. Interim results: influenza A (H1N1) 2009 monovalent vaccination coverage – United States, October–December 2009. MMWR Morb.Mortal.Wkly.Rep. 59:44–48. doi:mm5902a4 [pii]. 12. 2010. Interim results: state-specific influenza A (H1N1) 2009 monovalent vaccination coverage – United States, October 2009–January 2010. MMWR Morb.Mortal.Wkly.Rep. 59:363–368. doi:mm5912a2 [pii]. 13. 2010. Licensure of a high-dose inactivated influenza vaccine for persons aged >or=65 years (Fluzone High-Dose) and guidance for use – United States, 2010. MMWR Morb.Mortal.Wkly.Rep. 59:485–486. doi:mm5916a2 [pii]. 14. 2010. Outbreaks of 2009 pandemic influenza A (H1N1) among long-term-care facility residents – three states, 2009. MMWR Morb.Mortal.Wkly.Rep. 59:74–77. doi:mm5903a3 [pii]. 15. 2010. Policy statement – recommendations for prevention and control of influenza in children, 2010–2011. Pediatrics 126:816–826. doi:peds.2010-2216 [pii];10.1542/peds.2010-2216 [doi]. 16. 2010. Preliminary results: surveillance for Guillain-Barre syndrome after receipt of influenza A (H1N1) 2009 monovalent vaccine – United States, 2009–2010. MMWR Morb.Mortal.Wkly.Rep. 59:657– 661. doi:mm5921a3 [pii]. 59 WHO PUBLIC HEALTH RESEARCH AGENDA FOR INFLUENZA 17. 2010. Regional influenza A (H1N1) 2009 monovalent vaccination campaign – Skokie, Illinois, October 16–December 31, 2009. MMWR Morb.Mortal.Wkly.Rep. 59:909–913. doi:mm5929a3 [pii]. 18. 2010. Seasonal flu vaccination for healthcare workers? Drug Ther.Bull. 48:122–125. doi:48/11/122 [pii];10.1136/dtb.2010.11.0055 [doi]. 19. 2010. Seasonal influenza and 2009 H1N1 influenza vaccination coverage among pregnant women – 10 states, 2009–10 influenza season. MMWR Morb.Mortal.Wkly.Rep. 59:1541–1545. doi:mm5947a1 [pii]. 20. 2010. Seasonal influenza vaccination coverage among children aged 6 months–18 years – eight immunization information system sentinel sites, United States, 2009–10 influenza season. MMWR Morb.Mortal.Wkly.Rep. 59:1266–1269. doi:mm5939a2 [pii]. 21. 2010. Seasonal trivalent influenza vaccine for 2010–2011. Med.Lett.Drugs Ther. 52:77–79. 22. 2010. Start of the influenza season 2010–11 in Europe dominated by 2009 pandemic influenza A(H1N1) virus. Euro.Surveill 15. 23. 2010. Update: influenza activity – United States, August 30, 2009–March 27, 2010, and composition of the 2010–11 influenza vaccine. MMWR Morb.Mortal.Wkly.Rep. 59:423–430. doi:mm5914a3 [pii]. 24. 2010. Update: Recommendations of the Advisory Committee on Immunization Practices (ACIP) regarding use of CSL seasonal influenza vaccine (Afluria) in the United States during 2010–11. MMWR Morb.Mortal.Wkly.Rep. 59:989–992. doi:mm5931a4 [pii]. 25. 2011. [Adherence to the H1N1 vaccination recommendation in patients with Crohn’s disease or ulcerative colitis]. Dtsch.Med.Wochenschr. 136:939–943. doi:10.1055/s-0031-1275829 [doi]. 26. 2011. Adjuvant-containing H1N1 influenza vaccine pandemrix: narcolepsy in children.. 20:154. 27. 2011. Antigenic and genetic characteristics of influenza A(H5N1) and influenza A(H9N2) viruses for development of candidate vaccines viruses for pandemic preparedness – February 2011. Wkly. Epidemiol.Rec. 86:93–100. 28. 2011. Antigenic and genetic characteristics of zoonotic influenza viruses and development of candidate vaccine viruses for pandemic preparedness. Wkly.Epidemiol.Rec. 86:469–480. 29. 2011. Characteristics associated with seasonal influenza vaccination of preschool children – Oregon, 2006–2008. MMWR Morb.Mortal.Wkly.Rep. 60:981–984. doi:mm6029a2 [pii]. 30. 2011. Effectiveness and safety of the A-H1N1 vaccine in children: a hospital-based case-control study. BMJ Open. 1:e000167. doi:bmjopen-2011-000167 [pii];10.1136/bmjopen-2011-000167 [doi]. 31. 2011. Influenza A(H1N1) 2009 virus: current situation and post-pandemic recommendations. Wkly. Epidemiol.Rec. 86:61–65. 32. 2011. Influenza vaccination coverage among health-care personnel – United States, 2010–11 influenza season. MMWR Morb.Mortal.Wkly.Rep. 60:1073–1077. doi:mm6032a1 [pii]. 33. 2011. Influenza vaccination coverage among pregnant women – United States, 2010–11 influenza season. MMWR Morb.Mortal.Wkly.Rep. 60:1078–1082. doi:mm6032a2 [pii]. 34. 2011. Interim results: state-specific influenza vaccination coverage – United States, August 2010– February 2011. MMWR Morb.Mortal.Wkly.Rep. 60:737–743. doi:mm6022a3 [pii]. 35. 2011. Keeping up with your vaccinations. New guidelines include several changes. Harv.Womens Health Watch. 18:2–3. 36. 2011. Maternal and infant outcomes among severely ill pregnant and postpartum women with 2009 pandemic influenza A (H1N1) – United States, April 2009–August 2010. MMWR Morb.Mortal.Wkly. Rep. 60:1193–1196. doi:mm6035a2 [pii]. 60 BIANNUAL PROGRESS REVIEW AND REPORT 2010–2011 37. 2011. National and state vaccination coverage among adolescents aged 13 through 17 years – United States, 2010. MMWR Morb.Mortal.Wkly.Rep. 60:1117–1123. doi:mm6033a1 [pii]. 38. 2011. Place of influenza vaccination among adults – United States, 2010–11 influenza season. MMWR Morb.Mortal.Wkly.Rep. 60:781–785. doi:mm6023a3 [pii]. 39. 2011. Prevention and control of influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2011. MMWR Morb.Mortal.Wkly.Rep. 60:1128–1132. doi:mm6033a3 [pii]. 40. 2011. Prevention and control of influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2011. Am.J.Transplant. 11:2250–2255. doi:10.1111/j.1600- 6143.2011.03793.x [doi]. 41. 2011. Recommendations pertaining to the use of viral vaccines: influenza 2011. S.Afr.Med.J. 101:96. 42. 2011. Recommended composition of influenza vaccines for use in the 2012 southern hemisphere influenza season. Wkly.Epidemiol.Rec. 86:457–468. 43. 2011. Recommended composition of influenza virus vaccines for use in the 2011–2012 northern hemisphere influenza season. Wkly.Epidemiol.Rec. 86:86–90. 44. 2011. Seasonal influenza vaccination of the elderly. Prescrire.Int. 20:186–188. 45. 2011. Swedish Medical Products Agency publishes report from a case inventory study on Pandemrix vaccination and development of narcolepsy with cataplexy. Euro.Surveill 16. 46. 2011. TJC proposes 90% flu shot goal. Healthcare.Benchmarks.Qual.Improv. 18:70–71. 47. 2011. Update: influenza activity – United States, 2010–11 season, and composition of the 2011–12 influenza vaccine. MMWR Morb.Mortal.Wkly.Rep. 60:705–712. doi:mm6021a5 [pii]. 48. 2011. Update: influenza activity – United States, October 3, 2010–February 5, 2011. MMWR Morb. Mortal.Wkly.Rep. 60:175–181. doi:mm6006a4 [pii]. 49. Abbott, K. C., C. M. Yuan, and J. L. Lee. 2011. Nothing to sneeze at: efficacy and cost-effectiveness of the influenza vaccine in patients receiving long-term dialysis. Am.J.Kidney Dis. 57:651–653. doi:S0272-6386(11)00599-3 [pii];10.1053/j.ajkd.2011.02.380 [doi]. 50. Abdel-Haq, N. M. and B. I. Asmar. 2011. Novel swine – origin influenza A: the 2009 H1N1 influenza virus. Indian J.Pediatr. 78:74–80. doi:10.1007/s12098-010-0251-6 [doi]. 51. Abelin, A., T. Colegate, S. Gardner, N. Hehme, and A. Palache. 2011. Lessons from pandemic influenza A(H1N1): the research-based vaccine industry’s perspective. Vaccine 29:1135–1138. doi:S0264-410X(10)01676-2 [pii];10.1016/j.vaccine.2010.11.042 [doi]. 52. Abramson, Z. H., O. Avni, O. Levi, and I. N. Miskin. 2010. Randomized trial of a program to increase staff influenza vaccination in primary care clinics. Ann.Fam.Med. 8:293–298. doi:8/4/293 [pii];10.1370/afm.1132 [doi]. 53. Abramson, Z. H., O. Avni, O. Levi, and I. N. Miskin. 2011. Is the influenza vaccination rate of elderly patients affected by raising the vaccination rate of the staff at their primary health care clinics? Isr. Med.Assoc.J. 13:325–328. 54. Abu-Gharbieh, E., S. Fahmy, B. A. Rasool, and S. Khan. 2010. Influenza vaccination: healthcare workers attitude in three Middle East countries. Int.J.Med.Sci. 7:319–325. 55. Adalja, A. A., P. S. Crooke, and J. R. Hotchkiss. 2010. Influenza Transmission in Preschools: Modulation by contact landscapes and interventions. Math.Model.Nat.Phenom. 5:3–14. doi:10.1051/ mmnp/20105301 [doi]. 61 WHO PUBLIC HEALTH RESEARCH AGENDA FOR INFLUENZA 56. Adler-Moore, J., M. Munoz, H. Kim, J. Romero, T. Tumpey, H. Zeng, C. Petro, W. Ernst, S. Kosina, G. Jimenez, and G. Fujii. 2011. Characterization of the murine Th2 response to immunization with liposomal M2e influenza vaccine. Vaccine 29:4460–4468.
Load more

Recommended publications
  • Avian Influenza “Bird Flu”
    AVIAN FLU CONCERNS ESCALATE WORLDWIDE Louise Shimmel Avian influenza (“bird flu” as it is sometimes called in the press) is making its way into the news almost daily and causing worry among global health authorities, including the Centers for Disease Control and Prevention (CDC), World Health Organization (WHO), and the National Institute of Allergy and Infectious Diseases (NIAID). Avian influenzas are not new; they come in many types with widely varying levels of disease-causing capability. Definition: Influenza type A viruses, which include human and avian flu viruses, are categorized by H and N components, which denote specific types of proteins on their surface. The H component governs the ability of the virus to bind to and enter cells, which become virus-making factories. The N component governs the release of the newly made viruses from the animal host cell." [Reuters alertnet, 16 Nov 2005, edited.] There are 16 different HA subtypes and 9 different NA in type A influenza viruses. "There are only three known A subtypes of human flu viruses (H1N1, H1N2, and H3N2). When discussing “bird flu” we are talking about the influenza A subtypes chiefly found in birds. They do not usually infect humans, even though we know they can. [Fact Sheet, Avian Influenza, William T. Ferrier, DVM - prepared for falconers.] The virus making headlines is a specific subtype-H5N1-but there is more than one form of H5N1, specifically high- and low-pathogenic strains. The high-pathogenic form of H5N1 is the one in Asia that is causing global concern. There has been a low-pathogenic form of H5N1 found in migrating wild birds in Canada this fall, which is no cause for alarm.
    [Show full text]
  • Influenza Virus Infections in Humans October 2018
    Influenza virus infections in humans October 2018 This note is provided in order to clarify the differences among seasonal influenza, pandemic influenza, and zoonotic or variant influenza. Seasonal influenza Seasonal influenza viruses circulate and cause disease in humans every year. In temperate climates, disease tends to occur seasonally in the winter months, spreading from person-to- person through sneezing, coughing, or touching contaminated surfaces. Seasonal influenza viruses can cause mild to severe illness and even death, particularly in some high-risk individuals. Persons at increased risk for severe disease include pregnant women, the very young and very old, immune-compromised people, and people with chronic underlying medical conditions. Seasonal influenza viruses evolve continuously, which means that people can get infected multiple times throughout their lives. Therefore the components of seasonal influenza vaccines are reviewed frequently (currently biannually) and updated periodically to ensure continued effectiveness of the vaccines. There are three large groupings or types of seasonal influenza viruses, labeled A, B, and C. Type A influenza viruses are further divided into subtypes according to the specific variety and combinations of two proteins that occur on the surface of the virus, the hemagglutinin or “H” protein and the neuraminidase or “N” protein. Currently, influenza A(H1N1) and A(H3N2) are the circulating seasonal influenza A virus subtypes. This seasonal A(H1N1) virus is the same virus that caused the 2009 influenza pandemic, as it is now circulating seasonally. In addition, there are two type B viruses that are also circulating as seasonal influenza viruses, which are named after the areas where they were first identified, Victoria lineage and Yamagata lineage.
    [Show full text]
  • Influenza Vaccine Directive
    FAQS: INFLUENZA VACCINE DIRECTIVE FLU VACCINE UPDATES: Flu shots are now required for all staff working in healthcare settings in Alameda County and Berkeley, as recently ordered in a joint mandate by public health officers for Alameda County. This new mandate notes that with the flu season overlapping the COVID-19 pandemic, the risk is higher for health systems to be overwhelmed by patients with critical respiratory illness. Although there is no vaccine yet for COVID-19, the flu shot remains a safe and effective way to minimize the impacts of flu season and thousands of related doctor and hospital visits. Under Alameda County’s new order, all workers in healthcare settings must receive a flu vaccine to help protect themselves, teammates, patients and the wider community. Within our organization, all employees who work in Alameda County and have direct patient contact, must receive a flu shot no later than December 3, 2020. The new mandate specifies that you may only decline a flu shot if you provide a signed certification from your primary care provider stating that you have a medical condition that makes it unsafe to receive the flu vaccine. Masking is not an acceptable alternative to receiving the flu shot. If you haven’t yet received your flu shot, and you work in an Epic Care location within Alameda County, you must receive a flu vaccine on or before December 3, 2020. Flu vaccines are available at your local pharmacy, your doctor’s office, or Epic Care (while supplies last). If you are unable to obtain a flu vaccine through Epic Care, and you instead receive it from a different pharmacy or doctor’s office, the out of pocket cost of the vaccine will be reimbursed to you with a valid receipt for payment.
    [Show full text]
  • Assessment of Antigenic Difference of Equine Influenza Virus Strains by Challenge Study in Horses
    Accepted: 18 July 2016 DOI: 10.1111/irv.12418 SHORT ARTICLE Assessment of antigenic difference of equine influenza virus strains by challenge study in horses Takashi Yamanakaa | Manabu Nemotoa,b | Hiroshi Bannaia | Koji Tsujimuraa | Takashi Kondoa | Tomio Matsumuraa | Sarah Gildeab | Ann Cullinaneb aEquine Research Institute, Japan Racing Association, Shimotsuke, Tochigi, Japan We previously reported that horse antiserum against the Japanese equine influenza bVirology Unit, Irish Equine Centre, vaccine virus, A/equine/La Plata/1993 (LP93) exhibited reduced cross- neutralization Johnstown, Naas, Co. Kildare, Ireland against some Florida sublineage Clade (Fc) 2 viruses, for example, A/equine/Car- low/2011 (CL11). As a result, Japanese vaccine manufacturers will replace LP93 with Correspondence Takashi Yamanaka, Equine Research A/equine/Yokohama/aq13/2010 (Y10, Fc2). To assess the benefit of updating the Institute, Japan Racing Association, vaccine, five horses vaccinated with inactivated Y10 vaccine and five vaccinated with Shimotsuke, Tochigi, Japan. Email: [email protected] inactivated LP93 were challenged by exposure to a nebulized aerosol of CL11. The durations of pyrexia (≥38.5°C) and other adverse clinical symptoms experienced by the Y10 group were significantly shorter than those of the LP93 group. KEYWORDS challenge study, equine influenza, H3N8, inactivated whole vaccine 1 | INTRODUCTION showed limited cross- neutralization against some Fc2 viruses, for example, A/equine/Carlow/2011 (CL11) carrying the substitution Equine influenza
    [Show full text]
  • Novel H1N1 Influenza Updated Key Points June 11, 2009 • On
    Novel H1N1 Influenza Updated Key Points June 11, 2009 • On June 11, 2009, the World Health Organization (WHO) raised the worldwide pandemic alert level to Phase 6. • Designation of this phase indicates that a global pandemic is underway. • There are now community level outbreaks ongoing in other parts of the world. • State and international borders don’t matter at this point. The bottom line is that this new virus is among us all. • While U.S. influenza surveillance systems indicate that overall flu activity is decreasing in the United States, novel H1N1 outbreaks are ongoing in different parts of the U.S., in some cases with intense activity. • In the United States, this virus has been spreading efficiently from person-to-person since April and, as we have been saying for some time, we do expect that we will see more cases, more hospitalizations and more deaths from this virus. • Because there is already widespread novel H1N1 disease in the United States, the WHO Phase 6 declaration does not change what the United States is currently doing to keep people healthy and protected from the virus. • Thus there is no change to CDC’s recommendations for individuals and communities. • WHO’s decision to raise the pandemic alert level to Phase 6 is a reflection of epidemiological changes in other parts of the world and not a reflection of any change in the novel H1N1 virus or associated illness. • At this time, most of the people who have become ill with novel H1N1 in the United States have not become seriously ill and have recovered without hospitalization.
    [Show full text]
  • Chapter 19 Influenza
    Chapter 19: Influenza October 2020 19 Influenza Influenza The disease Influenza is an acute viral infection of the respiratory tract. There are three types of influenza virus: A, B and C. Influenza A and influenza B are responsible for most clinical illness. Influenza is highly infectious with a usual incubation period of one to three days. The disease is characterised by the sudden onset of fever, chills, headache, myalgia and extreme fatigue. Other common symptoms include a dry cough, sore throat and stuffy nose. For otherwise healthy individuals, influenza is an unpleasant but usually self-limiting disease with recovery usually within two to seven days. The illness may be complicated by (and may present as) bronchitis, secondary bacterial pneumonia or, in children, otitis media. Influenza can be complicated more unusually by meningitis, encephalitis or meningoencephalitis. The risk of serious illness from influenza is higher amongst children under six months of age (Poehling et al., 2006; Ampofo et al., 2006; Coffin et al., 2007; Zhou et al, 2012), older people (Thompson et al., 2003 and 2004; Zhou et al, 2012) and those with underlying health conditions such as respiratory or cardiac disease, chronic neurological conditions, or immunosuppression and pregnant women (Neuzil et al., 1998; O’Brien et al., 2004; Nicoll et al., 2008 and Pebody et al., 2010). Influenza during pregnancy may also be associated with perinatal mortality, prematurity, smaller neonatal size and lower birth weight (Pierce et al., 2011; Mendez-Figueroa et al., 2011). Although primary influenza pneumonia is a rare complication that may occur at any age and carries a high case fatality rate (Barker and Mullooly, 1982), it was seen more frequently during the 2009 pandemic and the following influenza season.
    [Show full text]
  • Characterizing Immunogenetic Factors Associated with Influenza Cross- Reactive Responses and Disease Severity
    Characterizing immunogenetic factors associated with Influenza cross- reactive responses and disease severity By Dr. Yoav Keynan M.D A Thesis submitted to the Faculty of Graduate Studies of The University of Manitoba in partial fulfilment of the requirements of the degree of DOCTOR OF PHILOSOPHY Department of Medical Microbiology University of Manitoba Winnipeg Copyright © 2013 by Yoav Keynan Acknowledgements: To my committee members: Dr. Coombs, Dr. Aoki, Dr. Soussi-gounni for your patience and invaluable advice, with diverse backgrounds, your input has been instrumental to the completion of this project. To my mentor, Dr. Fowke- for making my decision to migrate to your lab the best career decision I have made; for guiding me in this research project and for being an advocate and supporter along the course of the years. The most important lessons I have learned from you are not limited to science or grant writing, but more importantly, the optimism and positive attitude (sometimes bordering with delusion) that instills belief and motivation. To Dr. Rubinstein- for your advice and mentoring during the combined infectious diseases and PhD training. For the open doors, listening and support along the frequently bifurcating paths. To the Fowke lab team past and present- that make this lab a second home. Special thanks to Steve for your assistance over the past 8 years. To Dr. Plummer, for giving me the initial opportunity to embark on a research career in Winnipeg. To Dr. Ball for your support and collaboration. To the Ball Lab members, for the numerous fruitful discussions. To Dr. Meyers for the numerous projects and continued collaboration.
    [Show full text]
  • Flu Season Which Can Last As Late As May
    What Everyone Should Know About Seasonal Flu and the Seasonal Flu Vaccine Seasonal flu is not just a really bad cold. The flu is a contagious illness that affects the nose, throat, lungs and other parts of the body. It can spread quickly from one person to another. It can cause mild to severe illness, and at times can lead to death. Flu viruses are spread mainly from person to person through coughing or sneezing by people with influenza. Sometimes people may become infected by touching something - such as a surface or object - with flu viruses on it and then touching their mouth or nose. Every year in the U.S., on average: • 5% to 20% of the population gets the flu, • More than 200,000 people are hospitalized from seasonal flu complications and; • About 23,500 (and as high as about 48,000) people die from seasonal flu. The best way to prevent seasonal flu is by getting a flu shot or flu spray vaccination every year. When to get vaccinated against seasonal flu: Yearly flu vaccination should begin in September, or as soon as vaccine is available, and continue throughout the flu season which can last as late as May. This is because the timing and duration of flu seasons vary. While flu season can begin early as October, most of the time seasonal flu activity peaks in January, February or later. http://www.cdc.gov/flu/keyfacts.htm You can't get flu from getting a flu vaccine! The flu vaccine does not give you the flu.
    [Show full text]
  • Antiviral Drugs for Influenza Prevention and Treatment
    Antiviral Drugs for Influenza Prevention and Treatment Antiviral drugs are not a substitute for influenza (flu) vaccination. However, prescription antiviral medications play an important role in preventing and controlling the spread of influenza. These medications are a critical component of the U.S. Centers for Disease Control and Prevention (CDC) “Take 3” Actions to Fight the Flu. Take 3 urges everyone age 6 months and older to get vaccinated, follow good hand hygiene and cough/sneeze etiquette, and to take antiviral medications if they are prescribed.1 Influenza antiviral drugs are available to treat and prevent influenza: For Treatment: Antiviral drugs can reduce influenza symptoms, shorten the duration of illness, and prevent serious complications, like pneumonia, if taken within 48 hours of symptom onset.1,2 For Prevention: Antiviral drugs may also be prescribed to help prevent influenza in individuals who have been exposed to the virus. Antiviral drugs are about 70 to 90 percent effective when used as directed for prevention.3 For the 2014-15 flu season, CDC recommends use of either oseltamivir (Tamiflu®) or zanamivir (Relenza®) for treatment and prevention of influenza.2 Oseltamivir and zanamivir are dosed and administered differently, and are recommended for patients based on age and risk factors. A healthcare professional is best equipped to make an appropriate flu diagnosis and determine if antiviral treatment is recommended. More information about antiviral treatments is available at http://www.cdc.gov/flu/antivirals. Time Is of the Essence With antiviral therapy, timing is critical. A healthcare professional should be contacted at the first sign of influenza symptoms such as sudden onset of fever, aches, chills, and tiredness (for more information, see the fact sheet “Understanding Influenza”).
    [Show full text]
  • Dissertation Epidemiology, Ecology, and Evolution Of
    DISSERTATION EPIDEMIOLOGY, ECOLOGY, AND EVOLUTION OF CANINE INFLUENZA VIRUS H3N8 IN UNITED STATES DOGS Submitted by Heidi Lee Pecoraro Department of Microbiology, Immunology, and Pathology In partial fulfillment of the requirements For the Degree of Doctor of Philosophy Colorado State University Fort Collins, Colorado Fall 2012 Doctoral Committee: Advisor: Gabriele Landolt Carol Blair Richard Bowen Kathryn Huyvaert Copyright by Heidi Lee Pecoraro 2012 All Rights Reserved ABSTRACT EPIDEMIOLOGY, ECOLOGY, AND EVOLUTION OF CANINE INFLUENZA VIRUS H3N8 IN UNITED STATES DOGS Canine influenza virus (CIV) first emerged in dogs at a Florida racing track in 2004, although serological evidence suggests the virus has been circulating in the Unites States since as early as 1999. Phylogenetic analysis shows that CIV isolates are related to equine influenza virus of the Florida Clade 1 sublineage. However, sustained transmission of CIV among dogs and further genetic evolution of the virus has established CIV as a canine-specific influenza A virus (IAV). During the early years after emergence, studies determining the impact of CIV on dog populations were scarce. The few published findings were also alarming, with case fatality rates as high as 36% and seropositivity as high as 97% in certain dog populations. Despite these reports, the prevalence of CIV infection in dogs, the transmission dynamics among dog populations, risk factors for CIV infection, and how the virus was evolving within the canine host had yet to be examined. The research described here
    [Show full text]
  • ESCMID Online Lecture Library © by Author
    Albert Osterhaus Head Dept Virology Chairman ESWI CSO Viroclinics-Biosciences BV Library Pandemic flu and the anti-H1N1 vaccine: Lecture a retrospective view. author Onlineby © ESCMID ESCMID conference on the impact of vaccines on Public Health Prague, 2nd April 2011 Human influenza: three appearances Library Seasonal influenza (A: H3N2, H1N1; B) Lecture Avian influenza author (A: H7N7, H5N1…)Online by © PandemicESCMID influenza (A: H1N1, H2N2, H3N2, H1N1…?) INFLUENZA A VIRUS Recent zoonotic transmissions Library Subtype Country Year # Cases # Deaths H7N7 UK Lecture1996 1 0 H5N1 Hongkong 1997 18 6 H9N2 SE-Asia 1999author >2 0 H5N1 HongkongOnlineby 2003 2? 1 H7N7 Netherlands© 2003 89 1 H7N2 USA 2003 1 0 H7N3 Canada 2004 2 0 H5N1ESCMIDSE-Asia/M-East/ 2003-11 .>500 >300* Europe/W-Africa *CFR ~ 60% Library Lecture author Onlineby © ESCMID Confirmed H5N1 avian influenza virus endemic areas (poultry and wild birds) since 2003 Avian influenza A H5N1 virus - HA: Receptor specificity - Library Shinya et al., Nature 440, 2006 Lecture Van Riel et al., Science 2006 author Van Riel et al., Online Am J Pathol 2007 by Van Riel et al., © Am J Pathol 2009 Van Riel et al., ESCMID Am J Pathol 2010 Library Lecture author Onlineby © ESCMID Introduction - Attachment to the upper respiratory tract - Seasonal H3N2 Pandemic H1N1 HPAIV H5N1 Last four pandemics Library Lecture Credit: US National Museum of Health and Medicine author 1918 1957Online 1968 2009 “Spanish Flu” “Asian Flu” by “Hong Kong Flu” © ”Swine Flu” >40 million deaths 1-4 million deaths 1-4million deaths ??? A(H1N1)ESCMIDA(H2N2) A(H3N2) A(H1N1) Library Lecture author Onlineby © ESCMID Air traffic from Mexico ~ 1998 PB2,PA: Triple reassortant ~ 1968 ~ 1998 PB1: LibraryN-America ~ 1918 Classical swine HA, NP, NS: Lecture ~ 1979 NA, MA: authorEurasian swine Eurasia Onlineby A/California/4/2009 © PB2 PB1 The H1N1v flu virus PA Courtesy: Ron Fouchier HA NP ESCMID NA MA NS Library Lecture author Onlineby © ESCMID The Mexican flu virus..
    [Show full text]
  • Evolution and Divergence of H3N8 Equine Influenza Viruses
    pathogens Article Evolution and Divergence of H3N8 Equine Influenza Viruses Circulating in the United Kingdom from 2013 to 2015 Adam Rash 1,*, Rachel Morton 1, Alana Woodward 1, Olivia Maes 1, John McCauley 2, Neil Bryant 1 and Debra Elton 1 1 Animal Health Trust, Lanwades Park, Kentford, Newmarket, CB8 7UU, UK; [email protected] (R.M.); [email protected] (A.W.); [email protected] (O.M.); [email protected] (N.B.); [email protected] (D.E.) 2 Crick Worldwide Influenza Centre, The Francis Crick Institute, 1 Midland Road, London, NW1 1AT, UK; [email protected] * Correspondence: [email protected]; Tel.: +44-01638-751000 (ext. 1228) Academic Editor: Janet M. Daly Received: 22 December 2016; Accepted: 22 January 2017; Published: 8 February 2017 Abstract: Equine influenza viruses (EIV) are a major cause of acute respiratory disease in horses worldwide and occasionally also affect vaccinated animals. Like other influenza A viruses, they undergo antigenic drift, highlighting the importance of both surveillance and virus characterisation in order for vaccine strains to be kept up to date. The aim of the work reported here was to monitor the genetic and antigenic changes occurring in EIV circulating in the UK from 2013 to 2015 and to identify any evidence of vaccine breakdown in the field. Virus isolation, reverse transcription polymerase chain reaction (RT-PCR) and sequencing were performed on EIV-positive nasopharyngeal swab samples submitted to the Diagnostic Laboratory Services at the Animal Health Trust (AHT). Phylogenetic analyses were completed for the haemagglutinin-1 (HA1) and neuraminidase (NA) genes using PhyML and amino acid sequences compared against the current World Organisation for Animal Health (OIE)-recommended Florida clade 2 vaccine strain.
    [Show full text]